MXCT - MaxCyte signs strategic platform license with Be Biopharma April, 02 2024 08:37 AM MaxCyte Inc. 2024-04-02 08:37:14 ET More on MaxCyte MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M Seeking Alpha’s Quant Rating on MaxCyte Historical earnings data for MaxCyte Financial information for MaxCyte For further details see: MaxCyte signs strategic platform license with Be Biopharma